Exenatide Therapy Associated With Reduced Health Care Costs in Type 2 Diabetes

Once-weekly or twice-daily exenatide has been linked to reduced health care costs associated with type 2 diabetes.
Once-weekly or twice-daily exenatide has been linked to reduced health care costs associated with type 2 diabetes.

HealthDay News — For patients with type 2 diabetes, treatment with exenatide is associated with reduced health care resource use and costs compared with basal insulin regimens, according to a study published online in Diabetes, Obesity and Metabolism.

In a retrospective cohort study, Sarah E. Holden, from Pharmatelligence in Cardiff, UK, and colleagues estimated heath care resource use and related financial costs following exenatide-based regimens prescribed as once-weekly or twice-daily formulations versus basal insulin regimens. Data were included for patients with type 2 diabetes prescribed exenatide or basal insulin between 2009 and 2014 as their first recorded exposure to injectable therapy. A total of 8,723, 218, and 2,180 patients prescribed basal insulin, once-weekly and twice-daily, respectively, were included in the study. Overall, 188 patients prescribed once-weekly and 1,486 prescribed twice-daily were propensity score-matched to basal insulin patients in a 1:1 ratio.

The researchers found that total crude mean costs per patient-year were £2,765, £2,549, and £4,080 for once-weekly, twice-daily, and basal insulin, respectively, among unmatched cohorts. The adjusted annual cost ratio was 0.92 and 0.82 for once-weekly and twice-daily, respectively, compared with basal insulin. For the propensity score-matched subgroups, the corresponding costs were £2,646 versus £3,283 for once-weekly versus BI and £2,532 versus £3,070 for twice-daily versus basal insulin.

"Overall, treatment with once-weekly and twice-daily was associated with reduced health care resource use and costs compared with basal insulin," the authors write.

Several authors disclosed financial ties to Pharmatelligence. One author is an employee of AstraZeneca, which commercializes exenatide and funded the study.

Reference

Holden SE, Morgan CLI, Qiao Q, Jones-Jenkins S, Berni ER, Currie CJ. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: a retrospective cohort study [published online February 20, 2017]. Diabetes Obes Metab. doi:10.1111.dom.12916

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters